| scholarly article | Q13442814 |
| P50 | author | Daniela Capello | Q30303491 |
| Francesco Bertoni | Q40033742 | ||
| Annalisa Chiappella | Q51438316 | ||
| Lorenzo De Paoli | Q54365485 | ||
| Umberto Vitolo | Q56998074 | ||
| P2093 | author name string | G Gaidano | |
| A Conconi | |||
| D Rossi | |||
| A Castelli | |||
| S Franceschetti | |||
| E M Pogliani | |||
| S Rasi | |||
| A Ramponi | |||
| I Kwee | |||
| P2860 | cites work | The human glucocorticoid receptor: one gene, multiple proteins and diverse responses | Q28247745 |
| A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project | Q28251216 | ||
| Longitudinal data analysis for discrete and continuous outcomes | Q29547235 | ||
| Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity | Q29614981 | ||
| A case-control study of rheumatoid arthritis identifies an associated single nucleotide polymorphism in the NCF4 gene, supporting a role for the NADPH-oxidase complex in autoimmunity | Q33300467 | ||
| Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update | Q33303528 | ||
| Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma | Q33377621 | ||
| Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group | Q33773306 | ||
| Cumulative illness rating scale | Q34237005 | ||
| 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline | Q34523108 | ||
| CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group | Q34566901 | ||
| Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects | Q34713638 | ||
| Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases | Q35829421 | ||
| Prognostic biomarkers in diffuse large B-cell lymphoma | Q36371038 | ||
| Glutathione S-transferase polymorphisms: cancer incidence and therapy | Q36426775 | ||
| Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. | Q36502657 | ||
| Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities | Q36622610 | ||
| Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer | Q36974142 | ||
| Biostatistical aspects of genome-wide association studies | Q37064413 | ||
| Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma | Q40318856 | ||
| Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs | Q40408834 | ||
| Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms | Q43110263 | ||
| CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 | ||
| Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment | Q44271228 | ||
| C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils | Q44840248 | ||
| Promoter polymorphisms in glutathione-S-transferase genes affect transcription | Q44884458 | ||
| Reactive oxygen species limit neutrophil life span by activating death receptor signaling | Q44967331 | ||
| NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity | Q46837798 | ||
| The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines | Q46917682 | ||
| Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan | Q46920771 | ||
| FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. | Q53543347 | ||
| FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. | Q53599730 | ||
| Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation | Q80139390 | ||
| FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab | Q80667395 | ||
| Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19 | Q95801846 | ||
| P433 | issue | 6 | |
| P921 | main subject | diffuse large B-cell lymphoma | Q2626074 |
| B-cell lymphoma | Q4833719 | ||
| P304 | page(s) | 1118-1126 | |
| P577 | publication date | 2009-01-29 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 | |
| P478 | volume | 23 |
| Q36004460 | A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer |
| Q41709561 | ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. |
| Q53128895 | Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. |
| Q94938440 | Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer-A Children's Oncology Group ALTE03N1 report |
| Q53564509 | Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma. |
| Q36804526 | Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms |
| Q37738558 | Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification |
| Q55208199 | CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity. |
| Q98386581 | CD markers polymorphisms as prognostic biomarkers in hematological malignancies |
| Q38093137 | Cancer pharmacogenomics in children: research initiatives and progress to date. |
| Q33671281 | Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis. |
| Q39078275 | Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction. |
| Q38904284 | Cardiomyopathic Toxicity From Chemotherapy: Is There an Opportunity for Preemptive Intervention? |
| Q37159230 | Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors |
| Q35048393 | Doxorubicin pathways: pharmacodynamics and adverse effects |
| Q33646358 | Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy |
| Q89537275 | Effects of GSTA1 and GPX3 Polymorphisms on the Risk of Schizophrenia in Chinese Han Population |
| Q41430035 | Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines |
| Q40039502 | Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients |
| Q34062500 | Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma |
| Q58862883 | Genetic variants inSLC22A17 and SLC22A7are associated with anthracycline-induced cardiotoxicity in children |
| Q51816225 | Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. |
| Q35078505 | Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma show alterations of genes encoding the NADPH oxidase complex and impaired reactive oxygen species synthesis capacity |
| Q36822761 | Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients. |
| Q38874111 | Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. |
| Q33441706 | Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy |
| Q49049921 | Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel |
| Q50873463 | Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab. |
| Q45913850 | Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. |
| Q92861901 | Oxidative Stress-Related Gene Polymorphisms Are Associated With Hepatitis B Virus-Induced Liver Disease in the Northern Chinese Han Population |
| Q42130469 | Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine |
| Q38856218 | Pharmacogenetics of anthracyclines. |
| Q37932556 | Pharmacogenetics of genes across the doxorubicin pathway. |
| Q64077129 | Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment |
| Q38887034 | Pharmacogenomics and the treatment of acute myeloid leukemia. |
| Q36637796 | Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity |
| Q44028238 | Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation |
| Q55518023 | Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. |
| Q37833087 | Prognostication of diffuse large B-cell lymphoma in the rituximab era. |
| Q38838517 | Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity |
| Q36921775 | Risk factors for anthracycline-associated cardiotoxicity |
| Q38068541 | Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation |
| Q59334987 | SeqVItA: Sequence Variant Identification and Annotation Platform for Next Generation Sequencing Data |
| Q38606067 | Systems biology approaches to adverse drug effects: the example of cardio-oncology |
| Q89839532 | The Effects of Cruciferous Vegetable-Enriched Diets on Drug Metabolism: A Systematic Review and Meta-Analysis of Dietary Intervention Trials in Humans |
| Q38200683 | The emerging era of pharmacogenomics: current successes, future potential, and challenges |
| Q35236063 | The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. |
| Q42216535 | Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. |
| Q46409053 | Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. |
Search more.